PPARG and Hepatic fibrosis: Furthermore animal models for chronic pancreatitis [7] and liver fibrosis [21] did respond to treatment with TZDs, PPARγ ligands by ameliorated fibrotic responses, though there is also a report on a mouse model of hepatic fibrosis that was not responsive towards pioglitazone treatment [22].